ZIMMER BIOMET HOLDINGS INC

Zimmer Biomet (ZBH) trades near its 52‑week high with strong R&D, resilient supply‑chain, and patient‑centric implants poised for earnings growth and upside potential.

Zimmer Biomet (ZBH) posts a modest 0.01% rise, staying above its 200‑day SMA while peers dip. With a solid $18.1B cap, focused implant pipeline, and growing regulatory momentum, it offers steady, near‑term upside for investors seeking reliable medic…